SpringWorks and Seagen Enter into a Clinical Collaboration to Evaluate Nirogacestat + SEA-BCMA for R/R Multiple Myeloma
Shots:
- The companies will evaluate SpringWorks’ nirogacestat (GSI) + Seagen’s SEA-BCMA (Ab targeting BCMA) in patients with RRMM. The companies anticipate commencement of the study in H2’21
- Seagen to sponsor & conduct a P-I study to evaluate the safety- tolerability- and preliminary efficacy of the combination- and will assume all costs of study- other than the expenses related to the manufacturing of nirogacestat and IP rights
- The companies will form a joint development committee to manage the clinical study. Additionally- SpringWorks is conducting a global P-III DeFi Trial to evaluate nirogacestat as monothx. in adults with progressing desmoid tumors
| Ref: Globe Newswire | Image: Neurofibromatosis Network
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com